Cedars-Sinai develops tool to personalize presurgical breast cancer treatment

June 24, 2026

Key Highlights

BRIDGE predicts how breast cancer patients will respond to various presurgical treatments using biopsy data.
BRIDGE-Slide analyzes biopsy images to identify tumor composition without the need for costly genetic testing.
Both tools aim to be tested in clinical trials to validate their effectiveness in improving patient outcomes.
Effective presurgical treatment can shrink tumors, reduce the need for invasive surgery, and help prevent cancer recurrence.

6a3bf4429e3ba82d4857a967 Adobestock 1901960671

Cedars-Sinai Health Sciences University researchers have developed new technologies to advance personalized presurgical care for breast cancer patients. A news article written by Christina Elston describes their new tools.

BRIDGE is a predictive tool that can identify the best presurgical treatment for different breast cancer patients. It classifies multiple subtypes inside of tumors using biopsy samples collected when the patient received their diagnosis. Then, it notifies clinicians how the patient will respond to certain treatments.

Additionally, the researchers expanded BRIDGE, creating BRIDGE-Slide, eliminating the need for expensive genetic testing. The artificial intelligence-based tool identifies tumor composition from biopsy images. The scientists aim to test both technologies in clinical trials.

Effective presurgical treatment can impact patient outcomes by shrinking some tumors before surgery, leading to less invasive procedures, and helping prevent recurrence.